Nyxoah to Unveil OSA Neurostimulation Study Results by Early April
Nyxoah SA announced the upcoming release of efficacy and safety data from the DREAM US pivotal study on the Genio neurostimulation system for obstructive sleep apnea.
Nyxoah SA announced the upcoming release of efficacy and safety data from the DREAM US pivotal study on the Genio neurostimulation system for obstructive sleep apnea.
In a real-world case series, the Genio neurostimulator effectively reduced sleep apnea symptoms in patients with complete concentric collapse, demonstrating significant improvements in AHI and sleepiness.
The past year has brought relief that one bump in the pathway to neurostimulator use has been smoothed down for sleep apnea patients.
A patient success story highlights how the remedē System, an FDA-approved implantable stimulator for central sleep apnea, enhanced the quality of life for Maryland’s James Drake, 74.
Read MoreNyxoah SA has partnered with ResMed Germany to increase OSA awareness and therapy penetration in the German market.
Read MoreInspire Medical announced upcoming presentations and events highlighting its neurostimulator therapy for obstructive sleep apnea at the International Surgical Sleep Society and American Academy of Otolaryngology meetings.
Read MoreThe presentation will be led by sleep medicine physicians who will dive into the research and clinical findings that demonstrate the efficacy and benefits of neuromuscular electrical stimulation in treating OSA.
Read MoreNyxoah announced operating results for the second quarter and first half of 2023, emphasizing advances in its investigational device exemption trial designed to support the marketing authorization of the Genio neurostimulator system for the treatment of OSA.
Read MoreAn inexpensive machine commonly used for pain relief has shown to improve breathing in patients with obstructive sleep apnea, a clinical trial has found.
Read MoreInspire Medical Systems Inc reported second-quarter business results, marked by a series of US Food and Drug Administration regulatory approvals and submissions.
Read MoreThe newly appointed chief medical officer will serve full-time on Inspire’s executive leadership team and lead the company’s medical and clinical affairs functions.
Read MoreProSomnus announced plans to design a head-to-head clinical trial comparing its precision oral appliance therapy and hypoglossal nerve stimulation in treating patients with severe OSA.
Read MoreSleep apnea is common in children with Down syndrome. Sleep experts weigh in on what’s new in diagnosing and treating this patient population.
Read MoreWith further development, the technology could allow people to control dream plots and induce lucid dreams, according to REMspace researchers.
Read MoreThe company has completed all 115 implants in the DREAM trial and expects full 12-month data in the first quarter of next year.
Read MoreInspire Medical Systems Inc, a medical technology company focused on the development of solutions...
Read MoreNasdaq recognized the milestone by congratulating Signifier Medical on the Nasdaq Tower in Times Square, New York.
Read MoreThe reimbursement approval provides a pathway to open additional Inspire implanting centers in Belgium, while expanding access to care, according to Inspire Medical Systems.
Read More